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ABSTRACT 
Zhang, Shijun. M.S., Purdue University, May 2015. Hydrodynamic Delivery for 
Prevention of Acute Kidney Injury. Major Professor: Simon Atkinson. 
 
 
      The young field of gene therapy offers the promises of significant progress towards 
the treatment of many different types of human diseases. Gene therapy has been 
proposed as an innovative way to treat Acute Kidney Injury (AKI).  Through proteomic 
analysis, the upregulation of two enzymes, IDH2 and SULT1C2, within the mitochondrial 
fraction has been identified following ischemic preconditioning, a treatment by which 
rat kidneys are protected from ischemia. Using the hydrodynamic fluid gene delivery 
technique, we were able to upregulate the expression of IDH2 and SULT1C2 in the 
kidney. We found that the delivery of IDH2 plasmid through hydrodynamic fluid delivery 
to the kidney resulted in increased mitochondrial oxygen respiration compared with 
injured kidneys without gene delivery. We also found that renal ischemic 
preconditioning altered the membrane fluidity of mitochondria. In conclusion, our study 
supports the idea that upregulated expression of IDH2 in mitochondria can protect the 
kidney against AKI, while the protective function of upregulated SULT1C2 needs to be 
further studied.  
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CHAPTER 1. INTRODUCTION 
1.1 Acute Kidney Injury 
1.1.1 AKI: A Common and Important Clinical of Problem 
      Acute kidney injury is characterized by rapid loss of kidney function. The major 
manifestation decreased urine output resulting from a rapid decrease in Glomerular 
Filtration Rate (GFR). An increase in serum creatinine is commonly used to diagnose the 
onset of injury [1]. Acute kidney injury has been characterized by various definitions in 
the past decades. Many of the definitions are complex. The lack of a consensus and 
accurate definition of AKI made it difficult to determine the etiology and outcomes of 
AKI, and has been a major barrier to research on new, more effective treatments.   The 
organization named Acute Dialysis Quality Initiative (ADQI) was formed in early 2000. 
The members of ADQI, including international nephrologist and intensive care 
specialists, established the RIFLE (risk, injury, failure, loss, end-stage kidney disease) 
definition and staging system for AKI [2]. 
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      In 2007, the Acute Kidney Injury Network (AKIN) [3, 4], established by many of the 
original members of the ADQI group, released a modified RIFLE staging system in an 
attempt to increase the sensitivity and specificity of AKI diagnosis (Table 1). 
      In 2012 the Kidney Disease: Improving Global Outcomes (KDIGO) workgroup 
published their clinical practice guideline for AKI, which combines the definitions and 
staging systems defined by both ADQI and AKIN (Table 2). It is foreseeable that these 
guidelines will be widely adopted and the common set of parameters will help 
synthesize the information from different future clinical studies. 
       Acute renal failure has been a great healthcare concern in the U.S. because of its 
high prevalence in hospitals and high treatment cost. In 2011 AKI cost nearly $4.7 billion 
for approximately 498,000 hospital stays [5]. AKI accounts for 2%-7% of hospitalized 
patients per year. Moreover, the ICU population is at greater risk [6, 7], resulting from 
multi-organ disease and sepsis, the incident of AKI is steadily growing overall [8, 9]. 
Although prevention strategies and support measures are advancing, AKI still maintains 
a high morbidity and mortality, especially in the ICU population, where hospital 
mortality may exceed 50%, especially when there is other organ involvement. In 
addition to the 30%-70% mortality, the patients that survive their acute illness are at 
greater risk for chronic consequences, such as chronic kidney disease (CKD) and end-
stage renal disease (ESRD) [10-12]. AKI can lead to a variety of complications that lead to 
poor long term prognosis, including metabolic acidosis, high potassium levels, uremia, 
and changes in fluid balance [13].
 
 
3 
Table 1. RIFLE Classification System for Acute Kidney Injury. From [14]. 
Stage GFRa Criteria UOb Criteria 
Risk SCr
c increased 1.5-2 times baseline 
or GFR decreased > 25% UO < 0.5 mL/kg/h < 6h 
Injury SCr increased 2-3 times baseline or GFR decreased > 50% UO < 0.5 mL/kg/h > 12h 
Failure 
SCr increased >3 times baseline or 
GFR decreased > 75% or SCr ≥ 4 
mg/dL; acute rise ≥ 0.5 mg/dL 
UO < 0.3 mL/kg/h 
24h(oliguria) or anuria 12h 
Loss of function Persistent acute renal failure: complete loss of kidney function > 4 weeks 
ESRDd Complete loss of kidney function > 3 moths 
a GFR = glomerular filtration rate.              b UO = urine output.   
c SCr = serum creatinine.                              d ESRD = end-stage renal disease. 
 
 
 
 
 
 
 
Table 2. KDIGO Staging for AKI Severity. From [15] 
Stage Serum Creatinine Urine Output 
1 1.5-1.9 times baseline or ≥ 0.3 mg/dL increase < 0.5 mL/kg/h for 6h 
2 2-2.9 tunes baseline < 0.5 mL/kg/h for 12h 
3 
3 times baseline or increasing serum 
creatinine to ≥ 4 mg/dL or initiation of 
renal replacement therapy 
< 0.3 mL/kg/h for 24h 
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1.1.2 Signs and Symptoms of AKI 
      The symptoms of acute kidney injury are caused by the metabolic disturbances that 
result from decreased kidney function. Some of the symptoms are caused by the 
accumulation of urea and other nitrogenous waste products that cannot be properly 
excreted. These include fatigue, loss of appetite, headache, and nausea. There may also 
be significant increase in serum potassium that can cause severe disturbances in cardiac 
function [16]. The inability of the impaired kidney to excrete sufficient fluid from the 
body can affect the fluid balance, causing pulmonary edema and the accumulation of 
fluid, particularly in the distal regions of the limbs [17, 18].  
      AKI is usually diagnosed on the basis of characteristic laboratory findings, such as an 
increase in blood urea nitrogen and serum creatinine, or inability of the kidneys to 
produce sufficient amounts of urine (oliguria). However, these clinical parameters do 
not change significantly until relatively late in the injury process, so the last decade has 
seen an effort to identify new biomarkers of AKI that could allow the injury to be 
detected much earlier [19]. 
 
1.1.3 Classification of AKI 
      AKI can be caused by disease [20], crush injury [21, 22], contrast agents [23-25], 
some antibiotics [26], and more. How these drugs or events cause acute kidney injury 
remains controversial.  From the stand point of pathogenesis, the causes of acute kidney 
injury are commonly categorized into prerenal, intrinsic, and postrenal. 
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      Prerenal AKI is the most common in developed countries, in hospital inpatients, and 
particularly in critically ill patients. Prerenal AKI is triggered by a deficiency of blood flow 
to the kidney, otherwise known as renal ischemia. The systemic causes of prerenal AKI 
include low blood volume, low blood pressure, heart failure, liver cirrhosis, exposure to 
substances harmful to the kidney, inflammatory process in the kidney. Other potential 
causes of prerenal AKI include: renal artery stenosis and renal vein thrombosis by 
decreasing blood supply to the kidney [27].   
      Intrinsic AKI is caused by injury mechanisms that are intrinsic to the kidney itself. 
These types of injury can be subdivided based on the structures affected, such as 
glomeruli, tubules and renal interstitium. This internal damage may result in 
glomerulonephritis, acute tubular necrosis (ATN), and acute interstitial nephritis [28]. 
      Urinary tract obstruction may cause postrenal AKI. This can be a consequence of 
prostate problems, kidney stones, obstructed urinary catheter, or tumor masses in the 
bladder or urethra. 
 
1.1.4 Cellular Mechanisms of AKI 
      The mechanisms leading to acute kidney injury (AKI) are complicated and its causes 
vary. One of the most common cause of AKI, renal ischemia/reperfusion injury (IRI) [29-
30] is triggered by decreased delivery of oxygen and nutrients to the cells of the kidney, 
combined with a failure to remove waste products [31]. The kidney is extremely 
vulnerable to ischemia, due to the high level of metabolic activity required for the 
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normal function of the organ and the sensitivity of its cells to toxins. In addition to direct 
injury to the epithelial cells lining the tubule, ischemia also leads to vasoconstriction, 
endothelial damage, and activation of inflammatory processes.  
      The epithelium plays an important role in the process of kidney injury. In response to 
ischemia, epithelial cells lose normal cytoskeletal organization and cell polarity. The 
epithelial cells in the proximal tubule are the first to respond to the renal injury. The 
epithelial cells can lose their brush border membrane and microvilli and cell polarity 
with the dislocation of the adhesion molecules, Na+, K + ATPase and other membrane 
proteins on the epithelial cells [32]. Severe injury may lead to cell death by either 
necrosis or apoptosis [33]. In addition, the dislocation of adhesion molecules leads to 
viable epithelial cells lifting off the basement membrane. In some cases these cells can 
be shed into the lumen of the nephron and may be excreted in the urine, but some can 
interact with luminal proteins to obstruct the tubule lumen [34]. In response to renal 
injury, the epithelium generates inflammatory cytokines and vasoactive mediators to 
worsen vasoconstriction and inflammation and recruit a variety of inflammatory cells. 
      Endothelial cells may contribute to AKI in many ways. First, damaged endothelial 
cells diminish the blood flow of peritubular capillary, which adds to the effect of 
ischemia on the epithelial cells. The damaged endothelial cells contribute to 
vasoconstriction by decreasing production of nitric oxide and other vasodilators. The 
enhanced vasoconstriction is further compounded by small vessel occlusion due to the 
coagulation triggered by the immune response and the recruitment of white cells, and 
may lead to regional ischemia [35]. 
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      Third, damage to the endothelium can increase the permeability of the 
microvascular barrier and also reduce the number of microvessels in the outer medulla, 
which results in chronic hypoxia even when the acute injury is resolved [36, 37].  Chronic 
hypoxia is a condition in which tissues in the body are progressively deprived of oxygen. 
It results in a progressive increase fibrosis, further altering the structure of the kidney, 
which may lead in turn to less delivery of oxygen and nutrients, further epithelial cell 
injury, interfered regeneration progress, and a vicious cycle of further fibrosis [38, 39].  
      Both innate and adaptive immune responses play important role in ischemic injury. 
The innate immune response takes effect in the early response to injury in a non-
antigen-specific mode [40]. With ischemic injury, Toll-like receptors (TLRs) expressed by 
tubular epithelium are up-regulated by endogenous ligands which are released by 
damaged tissue, which can activate, mature dendritic cells (DCs) [41, 42]. Then DCs 
activate T lymphocytes, triggering an adaptive immune response. Besides TLRs, injured 
tubular epithelial cells express adhesion molecules [43], and other ligands for T cells 
[44], which activate these immune cells, leading to a further increase in inflammation.     
Proinflammatory cytokines and chemokines can be released by the epithelium to recruit 
immune cells [45]. Various cell types, including monocytes/ macrophages, DCs, and T 
cells, release factors leading to increasing vascular permeability and impairing tubular 
epithelial and endothelial cells [46]. This further adds to kidney injury [47]. 
      The cellular mechanism of kidney injury and repair is still not fully understood and 
better understanding is needed to improve therapies to prevent renal injury, accelerate 
the recovery of the organ, and minimize chronic kidney disease. 
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1.1.5 Management of AKI 
       Improved treatment and management of AKI will only be possible with better 
understanding of its underlying cause(s). The current treatment of AKI is mainly 
supportive in nature. The principles of management of established AKI are to treat or 
remove the cause (for example, treating sepsis or artery stenosis) and to use supportive 
measures to try to maintain homoeostasis while recovery of normal kidney function 
takes place. 
      Unfortunately, there are currently no specifically targeted therapies that have been 
developed which can lessen acute kidney injury or hasten recovery; thus, supportive 
treatment if the only option. This includes fluid, electrolyte and acid-based balance 
management [48]. Kidney transplant is the option if patients suffer from severe acute 
kidney injury.  
 
1.2 Ischemic Preconditioning 
      Ischemic preconditioning (IP) describes a commonly observed phenomenon, in 
which an organ can be made more tolerant to ischemia/reperfusion injury by 
preconditioning this organ with a previous, sub-lethal episode of ischemia. Murry and 
colleagues described the effect of ischemic preconditioning on dog heart in 1986 [49].  
      Soon after, the protection caused by ischemic preconditioning was shown in other 
animal models, besides dogs, including rabbits, rats, and guinea pigs [50, 51]. A number 
of studies have now shown that ischemic preconditioning using short periods of 
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ischemia is able to decrease the severity of a subsequent ischemic/reperfusion injury in 
various organs including the heart [51], liver [52], kidney [53], and lung [54].  
     Though the phenomenon of ischemic preconditioning was first described in the heart 
and is also extensively studied in myocardial infarction, there is now a substantial 
literature in the kidney that supports the finding that ischemic preconditioning can 
protect the kidney against a subsequent episode of ischemia [55].  
      The kidney is a vital organ in which preconditioning can have a protective effect. 
Given their demands for high energy and their complex vascular network, kidneys are 
extremely susceptible to ischemia/reperfusion [56, 57]. Animal experiments have 
confirmed that both local and distant preconditioning are effective in protecting the 
kidneys [58, 59].  
      Meta-analysis indicated that IP can reduce parameter of injury, including serum 
creatinine, blood urea nitrogen and structural alterations in the kidney observed by 
histology after kidney I/R injury as compared to controls, suggesting that IP effectively 
alleviates renal damage after kidney I/R injury. However, the mechanism behind the 
renal ischemia preconditioning phenomenon has yet to be elucidated. 
      Understanding the mechanisms responsible for ischemic preconditioning is 
important for formulating therapeutic strategies aimed at mimicking protective 
mechanisms – since preconditioning itself is not a plausible clinical approach. Currently, 
there is evidence for two types of intracellular mechanisms mediates the protective 
effect of ischemic preconditioning in other organs.  
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      One is the mitochondrial ATP-sensitive potassium (K+-ATP) channels and the other is 
a specific form of protein kinase C (PKC) [60]. The protective effect of ischemic 
preconditioning is believed to be more critically due to the opening of mitochondrial 
ATP-sensitive potassium channel or mitoKATP [61, 62].       
      In a cellular energy crisis it is proposed that, mitoKATP channels’ open and close to 
help to restore proper membrane potential. This includes restoring control over internal 
Ca2+ concentration and the degree of membrane swelling. This serves to maintain the 
proton gradient for mitochondria ATP synthesis [63].  
      PKC is an important regulator of the opening of mitoKATP channel [64]. Several 
pathways via which PKC regulates mitoKATP channel have been explored. Possible 
mechanisms include controlling release of oxygen radicals and controlling levels of Bcl-2 
proteins, which typically function as major regulators of apoptosis [65]. 
 
1.3 The Role of Mitochondria in AKI   
 
1.3.1 Function and Structure of Mitochondria 
      Mitochondria are intracellular organelles whose primary function is metabolic 
energy transduction and ATP synthesis. They also play vital roles in intermediate 
molecule metabolism, metal ion (calcium and iron) homeostasis, programmed cell death 
and are major sources and regulators of reactive oxygen species (ROS) [66]. 
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      A mitochondrion consists of an outer mitochondrial membrane and an inner 
mitochondrial membrane. The permeability of the outer mitochondrial membrane 
differs from that of inner mitochondrial membrane. The protein-based pores on the 
outer membrane allow proteins and ions to pass through relatively freely. Similar to the 
plasma membrane of a cell, the inner membrane is less permeable to ions and smaller 
proteins. The inner membrane is embedded with a number of proteins involved in 
electron transport and ATP synthesis. The mitochondrial matrix, surrounded by the 
inner membrane is a gel-like material, containing water and high concentrations of the 
enzymes involved in the citric acid cycle [67].  
      Adenosine triphosphate (ATP) used by all the energy-consuming activities of the cell, 
is predominantly generated in mitochondria through oxidative phosphorylation. 
Oxidative phosphorylation is achieved by the movement of electrons along electron 
transport chain (ETC). The generation of the electrochemical gradient requires oxygen 
consumption by the ETC, and is used to power ADP phosphorylation by complex V (the 
ATP synthase) [68]. Successive protein complexes, Complex I-IV, embedded in the inner 
mitochondrial membrane, form the ETC and are responsible for generation of the 
electrochemical gradient across the inner membrane. The role of these complexes is to 
transport electrons and pump protons across the mitochondrial inner membrane, and 
the fifth one called ATP synthase actually manufactures ATP from ADP and inorganic 
phosphate. Electrons, generated from the citric acid cycle, are carried to complex I 
(NADH dehydrogenase) and complex II (succinate dehydrogenase) by reduced 
nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) 
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respectively. Subsequently, electrons are passed to complex III (cytochrome bc1) 
through coenzyme Q (CoQ). Then cytochrome c carries the electrons from complex III to 
complex VI.  Finally electrons are transferred to the electron acceptor oxygen to form 
water. The energy generated from the electron flow is utilized to drive protons (H+) from 
matrix to intermembrane space at the level of complexes I, III, and VI to form an 
electrochemical gradient. This process is called chemiosmosis [69]. The gradient is used 
to reintroduce protons through the proton channel of complex V (ATP synthase). The 
proton flow drives the condensation of adenosine diphosphate (ADP) and inorganic 
phosphate to form ATP (Figure 1).  
      The mitochondrial membrane is composed of unique phospholipids and proteins. 
The interdependence of phospholipids and proteins provide a dynamic and fluid 
environment, which is crucial for mitochondrial function. For example, the membrane 
impermeability to protons enables the formation of proton gradient [70]. Proper 
membrane fluidity can organize the ETC complexes [71]. And changes in mitochondrial 
membrane fluidity can alter bioenergetics [72]. When the optimal membrane fluidity 
changes, mitochondrial functions are negatively impacted, e.g., membrane-associated 
enzymes function less efficiently as do membrane receptor-mediated signal 
transduction processes [73].  
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Figure 1. Mitochondrial Electron Transport Chain. Copyright © 2001 Benjamin 
Cummings, an imprint of Addison Wesley Longman, lnc. ADP, Adenosine diphosphate; 
ATP, Adenosine triphosphate; CoQ10, Coenzyme Q10; Cyt, Cytochrome; FAD, Flavin 
adenosine dinucleotide; Fe-S, Iron–sulfur cluster; FMN, Flavin mononucleotide; NAD+, 
Nicotinamide adenine dinucleotide; NADH, Reduced nicotinamide adenine dinucleotide. 
 
1.3.2 Ischemic Reperfusion Injury 
      Mitochondrial damage is a key contributor to AKI. Ischemia impairs the 
mitochondrial ETC by decreasing the activity of complexes and decreases the protection 
afforded by the antioxidant system. Short times of ischemia may increase the 
electronegativity of the ETC complexes and leakage of electrons, but may not be 
sufficient to alter the antioxidant system in mitochondria. During the short episodes of 
ischemia, the increased reactive oxygen species (ROS) produced following reperfusion 
(reintroduction of oxygen) can be reduced. Long ischemic period can trigger more 
profound changes within the mitochondria, such as decreased activity of the complexes 
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of the electron transport chain [74] and increased membrane permeability [75]. 
Decreased activity of ETC complexes causes low ATP production following reperfusion.  
       During ischemic injury, ATP is broken down to ADP, adenosine monophosphate 
(AMP) and inorganic phosphate. This break down is triggered by anaerobic metabolism. 
In addition to ATP breakdown, there is also an increase in resting cytosolic free (Ca2+) 
during ischemia which leads to mitochondrial Ca2+ overload. The accumulation of Ca2+, 
inorganic phosphate and ROS induces changes in permeability [76-78]. 
      The increased mitochondrial inner membrane permeability, called the mitochondrial 
permeability transition, is considered to drive apoptosis [79]. The mitochondrial 
permeability transition occurs by the formation of mitochondrial permeability transition 
pores (MPTP) located in the inner membrane. The opening of MPTP can not only 
diminish ATP production by causing proton leakage, but also allow small molecules and 
water to pass, which may result in matrix swelling and rupture of the mitochondrial 
outer membrane [80]. Among the released substances, activating factors, such as 
apoptosis inducing factor (AIF), cytochrome c, and Smac/DIABLO, are released into the 
cytosol to induce apoptosis [81]. 
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1.4 Gene Therapy: An Alternative Management of AKI 
 
1.4.1 Gene Therapy 
      Gene therapy is the introduction of exogenous or modified genes into a patient’s 
cells and tissues to treat inherited or acquired diseases. Gene therapy is a rapidly 
growing field of medicine that may hold the cure for many of the diseases and disorders 
of humankind. The completion of Human Genome Project accelerated the efforts to 
develop gene therapy as a viable treatment option, initially. 
      For disorders that result from single genetic aberrations, such as a mutation, 
truncation or deletion. Subsequently various efforts were launched to extend this 
treatment method to other monogenic disorders and a wider platform of ailments. 
 
1.4.2 Promises and Problems of Gene Therapy 
      The potential advantage of the technique, is that it holds the promise of eliminating 
and preventing hereditary diseases. It is very effective when the gene is delivered to 
tissue correctly and can fix the problem at the source. Drug side effects can also be 
avoided. Gene therapies are expected to be developed to treat genetic diseases, 
tumors, viral infections and neurodegenerative diseases. 
      In preclinical studies, gene therapy demonstrated robust improvements in animal 
models which carried mutations leading to different diseases. For example, in 2014, 
gene therapy was shown to improve muscle strength of a fatal congenital childhood 
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disease in large-animal models—dogs carrying a naturally occurring MIM1 gene 
mutation [82]. Currently, over 70% of gene therapy clinical trials are focused on cancer 
treatment. Most of the clinical trials are in Phase I or II, with less than 1% in Phase III 
[83]. The vast majority of these trials have focused primarily on the issue of safety.  
      Various genetic diseases are successfully improved by gene therapy, but the short-
lived nature of most current gene therapy approaches means the effect of most 
treatments are temporary. For example, in 1990, a retroviral vector adenosine 
deaminase (ADA) gene was transferred into the T cells of two children with severe 
combined immunodeficiency (ADA− SCID). After 2 years’ gene treatment, the number of 
circulating T cells normalized as did many cellular and humoral immune responses. But 
the effects only lasted for 4 years [84]. 
      So scientists must find better ways to deliver genes efficiently and achieve sustained 
expression. There are two categories of delivery vehicles ('vector'). One kind is non-viral 
vectors. Non-viral vectors can deliver DNA by direct injection, or mixing with polylysine 
or cationic lipids that allow the gene to cross the cell membrane. The potential 
advantage of non-viral methods is that the concerns about safety are not as high as 
when viral vectors are used. But most of these approaches are of poor efficiency of 
delivery and only give transient expression of the gene [85].  
      Viral vectors are currently widely used in gene therapy approaches. Viruses have 
specialized molecular mechanisms that have been refined by evolution to deliver DNA 
to cells and enable the persistent expression of transgene. However, there are pitfalls to 
viral vectors which may cause potential problems to the patient—toxicity, immune and 
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inflammatory responses, and gene control and targeting issues. In addition, the patient 
would be at risk that the viral vector may recover its ability to cause disease [86].  
Insertional mutagenesis by retroviral vectors has the potential to activate oncogenes. 
 
1.4.3 Vital Aspects to Ensure Advancements in Renal Genetic Medicine 
 
1.4.3.1 Exogenous Transgene Vectors 
      The first requirement for attempting gene therapy is to find capable technologies to 
transfer genes to various types of cells, tissues, and organs. The development of safe 
and effective vectors to deliver genes to cells is one of the key aspects to apply 
widespread genetic treatment. The vector must have the properties to target the 
specific cells for the disease, achieve sustained gene expression, and avoid pathogenic 
or adverse effects. 
      There are five classes of viral vectors derived from retroviruses, lentiviruses, 
adenoviruses, adeno-associated viruses, and herpes simplex-1 viruses. The five classes 
of viral vectors can be categorized in two groups, integrating vectors and non-
integrating vectors. Both retroviruses and lentiviruses are integrating vectors which can 
integrate their genomes into host chromatin. Integrating vectors transduce dividing 
cells. Because the genomes of integrating vectors can be gradually silenced over time, 
long term expression of transgene in diving host cells still cannot be promised. The 
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others are non-integration vectors whose genomes persist in the cell nucleus as 
extrachromosomal episomes. Non-integrating vectors can mediate sustained transgene 
expression in non-proliferating cells [87]. 
      Non-viral vectors, unlike viral vectors, require additional methods to ensure that 
efficient transfection is achieved. They can be delivered by injection, liposomes (cationic 
lipids mixed with nucleic acids), nanoparticles, and other methods. Compared to viral 
vectors, non-viral methods are safer for repeat administration [88], and easier for mass 
production. And most importantly, non-viral vectors have lower immunogenicity. 
 
1.4.3.2 The Construction of Non-viral Vectors  
      Distinct from the cell’s chromosomal DNA, plasmids are circular, double-stranded 
DNA (dsDNA) molecules. These extrachromosomal DNAs occur naturally in bacteria, 
yeast, and some higher eukaryotic cells. The most extensively used non-viral vectors are 
E. coli plasmids. There are three essential elements that vectors must have: (1) an origin 
of replication to allow the bacterial cells to replicate the plasmid DNA, (2) a drug-
resistance gene working as selectable marker, and (3) a region for DNA insertion. But if 
the plasmid containing antibiotic resistant gene is delivered to the patient, the patient 
could obtain antibiotic resistance. Expression vectors require sequences that encode 
for: (1) A polyadenylation tail: to protect the mRNA from exonucleases and ensure 
translational termination and stabilize mRNA. (2) Kozak sequence: is necessary for 
ribosome assembly. (3)Promoter: an essential element to initiate transcription of the 
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vector's transgene.  (4)Reporter genes: can be used to identify that the plasmid contains 
inserted DNA sequence. (5)Targeting sequence: can target the expressed protein to 
specific locations. (6)Protein purification tags: can be used for purifying the expressed 
protein.  
 
1.4.3.3 Efficient Renal Gene Delivery Techniques 
         Unlike viral vectors which have efficient molecular mechanism to infect hosts, non-
viral vectors cannot pass through cellular barriers to access host DNA [89]. In order to 
enable the expression of transgenes, methods must facilitate the non-viral vectors to 
pass through the cell membrane, access the nucleus and get into the host chromatin. 
       In 1990, a direct injection of naked DNA into murine models was first demonstrated 
in vivo. The effects of this protein expression vectors was long lasting, but localized [90]. 
Today a number of other non-viral methods have been developed to deliver naked DNA 
and each has advantages and disadvantages. 
      Another promising non-viral route is to package plasmid DNA with liposomes and 
administer the mixture by intravenous injection.  Like other non-viral routes these have 
low toxicity and low immunogenicity. Cationic lipids can bring plasmid DNA in the 
cytoplasm by interacting with the cell membrane. Once cationic lipids are absorbed by 
cytoplasm, plasmid are released from endosomal compartments [91]. Besides 
liposomes, biocompatible, biodegradable polymers can be used as plasmid carriers in a 
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similar way. These non-viral routs are utilized to treat cancer and cystic fibrosis, 
however, the transfection efficiency needs to be improved [92]. 
      Once the genetic materials enter the nuclei, it works to either enable or inhibit the 
expression of the gene product of interest in transformed cells and their progeny. 
      Due to the complex renal vascular structures and various vascular permeability, gene 
transfer in the kidney faces the problem of low efficiency. Proximal tubule epithelial 
cells have the potential to act as a transgene target, because they have great capacity to 
endocytose exogenous materials [93, 94]. But the glomerular filtration barrier blocks the 
transgene’s accessibility to the apical domain of epithelial cells, which limits the uptake 
of transgene [95]. It is possible that gene vectors could access the proximal tubule 
epithelial cells through peritubular capillaries. But the efficiency of the accessibility is 
unknown. 
      Many studies have delivered adenovirus vectors to the kidney via different methods 
and observed different levels of gene expression. The adenovirus was delivered through 
arterial injections in normal [96] and cystic rats; pelvic catheter infusions in normal rats 
[97]; and tail vein [98] and cortical micropuncture [99] injections in uninjured animals. 
Due to the complex anatomy of the kidney, the gene expression levels differed in renal 
cell types and anatomic regions in the kidney. The variable results appear to depend on 
transgene infusion site, volume and rate, as well as the organ temperature and the use 
of vasodilators.  
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      In contrast, hydrodynamic fluid delivery has been developed to address these 
challenges by increasing vascular permeability to efficiently deliver exogenous 
substances throughout the kidney. 
      In sum, there are several challenges to renal transgene delivery. The techniques 
presented have provided varied levels of success and are capable of inducing harmful 
side effects. Therefore, there is a critical need for the development of safe and 
efficacious transgene delivery options. Such techniques would assist the delivery of 
clinically relevant genes that can induce transient genetic modifications with minimal 
physiological interference or damage, and help realize the promise of gene therapy. 
 
1.5 A Novel Renal Gene Delivery Technique: Hydrodynamic Fluid Delivery 
 
1.5.1 Hydrodynamic Fluid Delivery 
      Hydrodynamic delivery, developed in the late 1990s, was utilized to deliver plasmid 
DNA in whole animals via intravascular injection. The pressure in capillaries generated 
by hydrodynamic injection enhanced endothelial and parenchymal cell permeability 
[100-102].  
      This new non-viral gene delivery approach is remarkably efficient, safe, and 
convenient. In some cases, hydrodynamic delivery enables long-lasting transgene 
expression in transfected animals and is shown to be long-lasting and reach therapeutic 
levels [103-110].  
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      Early studies of hydrodynamic gene delivery involved the delivery of genes to the 
liver, and established that this is a potentially effective method for targeted delivery to a 
particular organ. Now more hydrodynamic delivery procedures have been developed to 
adapt to other gene delivery applications and for use in other organs [111-115]. 
 
1.5.2 Mechanism of Hydrodynamic Fluid Delivery 
           Hydrodynamic fluid delivery is aimed at generating increased fluid pressures 
within thin, and stretchable capillaries. It is believed that enhanced fluid flow generated 
from pressurized injections generates transient pores on the capillary endothelium [116] 
and epithelium [117]. The fluid flow and disruption of the physical barriers separating 
the target cells from the circulation enables DNA or other macromolecules to pass 
through the plasma membranes of the surrounding parenchyma cells. With time, the 
exogenous molecules are trapped inside the parenchyma cells when the membrane 
pores close [118-120]. Much of this proposed mechanism is speculative. 
 
1.5.3 Hydrodynamic Fluid Retrograde Renal Vein Delivery 
      In less than a decade, hydrodynamic gene delivery has been widely accepted as a 
tool for gene therapy studies. Several laboratories are focusing on adapting the 
hydrodynamic delivery method for studies in the kidney. Renal artery, renal vein, and 
ureter may be ideal delivery paths for hydrodynamic renal gene delivery [121]. 
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      Hydrodynamic fluid delivery via renal vein injection has been shown to achieve 
widespread transfection of tubular epithelial cells using plasmid and viral vectors [122]. 
The renal vein is easy to access and it also provides a viable injection site for 
hydrodynamic delivery. Compared to other procedures, hydrodynamic fluid renal vein 
delivery is relatively easy for surgeons to perform, achieves wide, and long lasting 
expression of the exogenous gene, and produces minimal injury to the kidney. 
 
1.6 Kidney Protective Genes Encoding IDH2 and SULT1C2 
 
1.6.1 Mitochondrial Modifiers: IDH2 and SULT1C2 
 
1.6.1.1 Overview of IDH2 
      Isocitrate dehydrogenase 2 (IDH2) is a member of Isocitrate dehydrogenases (IDHs), 
which catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate. The 
catalytic function of IDHs is crucial [123]. All eukaryote genomes contain three IDH 
genes, IDH1, IDH2 and IDH3. IDH3 is a NAD+-dependent enzyme located in the 
mitochondrial matrix and acts in the Krebs cycle [124]. The other two isocitrate 
dehydrogenases, IDH1 and IDH2, are NADPH-dependent enzymes and share similar 
structure [125]. IDH3 irreversibly decarboxylates isocitrate to yield 2-oxoglutarate while 
reducing NAD+ to NADH, whereas IDH1 and IDH2 catalyze reversible reactions, either 
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decarboxylating isocitrate to 2-oxoglutarate while reducing NADP+ to NADPH or acting 
in the reductive carboxylation (reverse) reaction to convert 2-oxoglutarate to isocitrate 
while oxidizing NADPH to NADP+. 
      IDH1 is located in the cytoplasm and peroxisomes, and highly expressed in the liver. 
Besides IDH1 having the capacity to catalyze the conversion of isocitrate to α-
ketoglutarate, it has been shown that IDH1 is involved in cellular metabolic processes 
such as lipid and glucose metabolism [126, 127], and cellular defense against reactive 
oxygen species and radiation [128-130].  
      IDH2 is localized to the mitochondrial matrix, and highly expressed in heart, muscle, 
and activated lymphocytes [131]. IDH2 not only regulates the citric acid cycle, but also 
protects cells against oxidative stress [132, 133]. 
      IDH1 and IDH2 caught the interests of scientists, because their mutations could 
contribute to tumorigenesis and cancer progression through indirect effect that increase 
the overall mutation rate in cancer cells. Cancers characterized by mutations in either 
IDH1 or IDH2 include gliomas and acute myeloid leukemia [134]. 
 
1.6.1.2 SULT1C2 
      SUL1C2 is located in the cytoplasm and is a member of the sulfotransferase family. 
Sulfotransferase can catalyze the transfer of the sulfonate moiety from PAPS (3’-
phosphoadenosine 5’-phosphosulfate) to many substrates. Sulfate conjugation is an 
important pathway in the biotransformation of many neurotransmitters, hormones, 
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drugs and other xenobiotics. In mammals, sulfotransferase are divided into two 
subfamilies, SULT1 and SULT2. Members of the SULT1C subfamily, including SULT1C1 
and SULT1C2, have been shown to catalyze the sulfate conjugation of thyroid hormones 
and carcinogenic hydroxyarylamines. The significance of this activity in the context of 
renal ischemic injury is not obvious. 
 
1.6.2 Discovery of the Protective Function 
 
      Ischemic preconditioning (IP) is utilized to protect organs by producing resistance to 
the injury normally caused by the loss of blood supply, and thus oxygen. If the blood 
supply to the kidney of the rat is impaired for a short time then restored, the kidney 
becomes robustly protected from a subsequent ischemic insult for an extended period 
of time [135]. 
      Ischemic preconditioning can protect the kidney against subsequent ischemia 
/reperfusion injury, but the mechanism is not fully understood. One proposed 
mechanism is that it results in altered expression of mitochondrial proteins or 
cytoplasmic proteins associated with mitochondria that affords a resistance to 
ischemic/reperfusion injury. Proteomic analysis carried out by Dr. Bacallao, Dr. Basile 
and Dr. Witzmann, showed that several proteins in renal mitochondria were elevated 
following preconditioning. Liquid chromatography- mass spectroscopy (LC/MS) was 
used to analyze the proteome of kidney cortical mitochondria isolated following 14 days 
of recovery from ischemic preconditioning. Two of the upregulated proteins were 
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selected for further analysis; IDH2 and SULT1C2. Several experiments performed by Dr. 
Peter Corridon demonstrate that hydrodynamic delivery of IDH2 and SULT1C2 genes can 
protect the kidney from AKI generated from IRI. 
      Serum creatinine measurements were carried out by Dr. Corridon. Serum creatinine 
clearance is a standard biomarker used to gauge renal function. Creatinine is a 
byproduct of normal muscle metabolism and should be generated by the muscles and 
excreted by the kidney at a relatively constant rate. When kidney function is impaired, 
nephron capacity is altered to limit renal clearance. Such an event can eventually reduce 
the excretion of creatinine, thereby often decreasing urinary creatinine excretions, 
while increasing serum creatinine levels [136]. 
      On the 7th day after each rat received a hydrodynamic injection containing either 
saline or a plasmid, they were subjected to moderate ischemia-reperfusion injury (IRI). 
The serum creatinine levels were monitored for a week after inducing IRI and showed 
that the hydrodynamic delivery of IDH2 or SULT1C2 genes was sufficient to blunt the 
effect of IRI in Sprague Dawley rats. Specifically, serum creatinine levels in these rats 
remained within normal levels despite being subjected to moderate IRI, when compared 
to rats that received hydrodynamic or tail injections of saline or fluorescent plasmids 
(Figure 2). 
      Dr. Corridon also evaluated mitochondrial activity in vivo using 2-photon 
fluorescence microscopy and the potential-sensitive dye TMRM (tetramethylrhodamine 
methyl ester). TMRM is a fluorescent probe which binds to the inner and outer leaflets 
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of the inner mitochondrial membrane. And the fluorescent intensity of TMRM can be 
used to monitor the membrane potential of mitochondria. 
      Jugular vein infusions of the mitochondrial membrane potential-dependent dye 
TMRM were used to gain insight into mitochondria function in various groups of live 
rats. TMRM fluorescent signal intensities measured in rats that previously received 
hydrodynamic injections of either IDH2 or SULT1C1 plasmid vectors, as well as those 
that received ischemic preconditioning, were significantly greater than those measured 
in rats that received hydrodynamic saline injections or uninjected normal rats. 
Mitochondrial potential was maintained in animals that received hydrodynamic delivery 
of either gene relative to controls (Figure 3). These data outline a possible increase in 
mitochondrial activity related to the upregulation of the mitochondrial enzymes 
facilitated by hydrodynamic IDH2 and SULT1C1 gene delivery and ischemic 
preconditioning.       
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Figure 2. Serum creatinine measurements of hydrodynamically treated rats. 
Hydrodynamic-based IDH2 and SULT1C2 enzyme upregulation protects the kidney from 
moderate forms of renal injury. Rats hydrodynamically treated with plasmids encoding 
mitochondrial proteins seven days earlier, appear less susceptible to moderate 
ischemia-reperfusion injury. 
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Figure 3. Mitochondria membrane potential activity examined in nephron segments of 
various live rats. Image (A) represents baseline autofluorescence in a normal rat that 
did not receive the TMRM dye. In the other cases live rats received hydrodynamic 
injections of (B) saline; (C) IDH2 plasmids; (D) SULT1C2 plasmids; (E) SULT1C2 plasmids 
in the uninephrectomized rats. The rat imaged in (E) was subjected to ischemic-
preconditioning and did not receive a hydrodynamic injection. Rats (B) through (F) were 
given TMRM via jugular vein after being exposed to 30 minutes of ischemia one week 
after receiving hydrodynamic injections or ischemic preconditioning, and were imaged 
approximately 15-20 minutes after receiving jugular vein infusions of TMRM and renal  
blood flow was restored. 
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1.7  In Vitro Assays for Mitochondrial Respiration  
      In vitro measurements of mitochondrial respiration use manipulations to monitor 
several different functional “states”. Chance and Williams (1955) defined respiratory 
states and designed a protocol for mitochondrial activity measurement with isolated 
mitochondria (Figure 4). The classical titration protocol starts with State 1. In State 1, 
mitochondria are added to an isosmotic medium containing sufficient phosphate. 
Respiration is slow in State 1, because mitochondria are under respiratory substrate 
starvation. In State 2, substrate is added (e.g., succinate, pyruvate, etc.). Mitochondrial 
respiration is still low in the presence of substrate due to the absence of any added ADP. 
In State 3, ADP is added and respiration is activated at the presence of substrate and 
ADP. In this State, respiration is high and can be represented as the slope of oxygen 
consumption.  ADP is gradually depleted by phosphorylation to ATP.  As State 3 
continues, respiration markedly decreases to a slower rate due to the limited ADP. That 
state is State 4. Finally, in State 5, depleted oxygen in the closed oxygraph chamber 
restricts respiration [137]. The mitochondrial respiration can be measured through the 
consumption rate of oxygen during the procedure in the presence of State 3. 
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Figure 4. Graph of consumption of O2 (adapted from Curti & Uenura, 1998) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 
1.8 Mitochondria Membrane Fluidity Measurement: Laurdan 
      The function of membrane proteins and, particularly, the interactions between 
them, are strongly influenced by the local environment in the lipid bilayer. This affects 
the likelihood of protein-protein interactions that are functionally important, such as 
those between the components of the ETC. In my study, the fluidity of mitochondria 
membrane was measured by using Laurdan (6-Dodecanoyl-2-
Dimethylaminonaphthalene). Laurdan is a fluorescent membrane probe synthesized by 
Gregorio Weber in 1979. It is sensitive to the polarity of its environment in the bilayer. 
The emission spectrum of laurdan can shift according to the dipolar relaxation of 
laurdan in the liquid environment, reflecting both the polarity of the environment and 
the mobility of the probe molecules. Laurdan molecules distribute homogeneously in 
the lipid bilayer and move freely. In particular, the emission spectrum of laurdan differs 
when it is incorporated into a lipid bilayer in the liquid crystalline phase as compared to 
the gel phase, two states that are proposed to significantly affect the activity of 
membrane proteins and complexes. It has been confirmed that the emission maximum 
of laurdan is centered at 490 nm when the lipids are in a liquid-crystalline phase, and 
the emission maximum is centered at 440 nm when the lipids are in a gel-phase. The 
shift of emission of laurdan can be expressed using Generalized Polarization, GP= (I440-
I490)/(I440+I490). GP values above zero reflect a preponderance of the gel phase, while 
GP values below zero are indicative of more liquid-crystalline area. Because of these 
properties, laurdan has become a useful tool to detect changes in membrane phase 
properties [138, 139]. 
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1.9  Hypothesis 
      Our hypothesis is that hydrodynamic retrograde renal vein fluid delivery of the genes 
IDH2 and SULT1C2 can modify mitochondria to prevent subsequent acute kidney injury 
caused by ischemia-reperfusion injury, and will mimic the effect of ischemic 
preconditioning. IDH2 and SULT1C2 that have been shown by our collaborators to be 
upregulated in the kidneys of rats that are resistant to moderate ischemia-reperfusion 
injury. Thus, we simulated this renal regulatory and protective process in kidneys by 
transferring certain concentrations of these genes via hydrodynamic delivery. 
      In order to identify the efficiency of transferring plasmids in kidney delivered by 
hydrodynamic fluid delivery, we used in situ PCR to detect the amplified transgenes and 
western blotting was used to detect the upregulation expression of these genes. 
      As IDH2 plays an indispensable role in the TCA cycle, we hypothesized that the 
upregulation of IDH2 could enhance the mitochondria respiration capability. We 
expected that when IDH2 plasmid was delivered to rats and they were then subjected to 
moderate ischemia/reperfusion injury, the mitochondria activity of these kidneys would 
be improved compared to controls. The role of SULT1C2 in mitochondria function, if 
any, is unknown. But as a member of sulfotransferase family, it could catalyze the 
sulfate conjugation to mitochondria membrane. Both sulfate iron and membrane 
phospholipids have a negative charge, and modification of the overall charge on the 
membrane or of particular components could alter the fluidity of mitochondria 
membrane.  We hypothesize that SULT1C2 protects the proper function of mitochondria 
by regulating the fluidity of the mitochondrial membrane.
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Cell Culture and Live Animals 
 
2.1.1 Cell Culture 
2.1.1.1 Mouse Kidney Cell Culture 
      We used the S3 segment of the proximal tubule epithelial cells [140] cultured in a 
mixture of 500 ml of essential media with, 7.5% of sodium bicarbonate, 7% of fetal 
bovine serum (FBS), and 1% of streptomycin (Fisher Scientific, Pittsburgh, PA) The cells 
were grown in a 37°C, 5% CO2-38% CO2 humid incubator. 
 
2.1.1.2 Live Rats 
     Male Sprague Dawley (Harlan Laboratories, Indianapolis, IN), Frömter Munich Wistar 
(Harlan Laboratories, Indianapolis, IN) with weight ranging from 250gm to 400 gm, were 
used for these studies. The rats were given free access to standard rat chow and water 
throughout our studies. Experiments were conducted in accordance with the National  
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Institutes of Health Guidelines and were approved by the Indiana University School of 
Medicine Institutional Animal Care and Use Committee. 
 
2.2 Ischemia/Reperfusion Injury 
 
2.2.1 Unilateral Clamp Model 
      Rats were anesthetized with intraperitoneal injections of 60 mg/kg pentobarbital 
(Hospira, Inc., Lake Forest, IL and Custom Med Apothecary, Indianapolis, IN), and then 
placed on a heating pad to maintain normal physiological temperature. Using a standard 
model to generate renal ischemia-reperfusion injury, unilateral (left) renal pedicle 
clamps were applied to occlude blood flow for periods of 30-45 minutes, which 
corresponds to moderate/acute kidney injury. At the end of each injury period, the 
clamp was removed to reinstate renal blood flow and animals were allowed to recover. 
 
2.2.2 Ischemic Preconditioning 
      Rats were again anesthetized in the manner described above and subjected to 
bilateral pedicle clamps to occlude renal blood flow for periods of 30-45 minutes. The 
incisions were also temporarily closed during ischemia. The animals were then allowed 
to fully recover for a period of 14 days. 
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2.3 Plasmid Vectors 
      We prepared plasmid DNA for gene therapy using Qiagen Maxi Prep systems 
(Qiagen, Chatsworth, CA, USA). The DNA was suspended in saline for gene delivery. 
These plasmids encode: enhanced EGFP-occludin (a gift from Dr. Clark Wells, IUSM) and 
H2B-tdTomato (a gift from Dr. Richard Day, IUSM). We used non-fluorescently labeled 
plasmid vectors that encode mitochondrial enzymes isocitrate dehydrogenase [NADP], 
mitochondrial (IDH2) and sulfotransferase (OriGene Technologies, Inc., Rockville, MD). 
The IDH2 vector was an ORF clone of Homo sapiens isocitrate dehydrogenase 2 
(NADP+), mitochondrial (IDH2), nuclear gene encoding mitochondrial protein as 
transfection-ready DNA. The sulfotransferase vector was an ORF clone of Homo sapiens 
galactose-3-O-sulfotransferase 2 (GAL3ST2) as transfection-ready DNA. For these 
hydrodynamic injections, the range of doses we used was 1 to 3 µg of plasmid DNA per 
gram of body weight. 
 
2.4 Cell Culture Transfection 
      Immortalized cell cultures were grown in a 35 mm glass bottom, No. 1.5 coverslip 
dishes, with standard thickness of 0.17 millimeters (Corning Inc., Corning, NY). 
We followed the Effectene Transfection Reagent protocol provided by Qiagen (Valencia, 
CA), for plasmid-based transfections. We transfected cells at a multiplicity of infection 
(MOI) of 10:1, and a 24 hour incubation period using both types of viral vectors. 
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2.5 Cell and Tissue Imaging 
 
2.5.1 Confocal Fluorescence Imaging of Live Cells 
      All confocal imaging studies were conducted an Olympus FV 1000-MPE 
Microscope (Olympus, Tokyo, Japan). Cell cultures were grown in 35 mm glass bottom, 
No. 1.5 coverslip dishes, with standard thickness of 0.17 millimeters (Corning Inc., 
Corning, NY). The dishes were placed above the objective and the microscope was set to 
acquire 512×512 blue-, green- and red-pseudo-color images. To minimize both 
photoxicity and photobleaching, we reduced both the energy level of the excitation light 
and the duration of excitation. We also used a Warner DH-35 dish and OW objective 
warmers to maintain culture temperatures as needed for prolonged imaging sessions. 
 
2.5.2 Intravital Two-Photon Fluorescence Microscopy 
      In anesthetized rats, we shaved the left flank and made vertical incisions to 
externalize the left kidney. The kidney was then placed inside a glass bottom dish 
containing saline, which was set above either a 20X or 60X water immersion objective 
for imaging, with the animal’s body acting as weight to stabilize the kidney in this 
position. A heating pad was then placed over the rat to maintain its core temperature. 
Fluorescent images were acquired from externalized organ within 800-860 nm 
excitation wavelength range207. Measurements were made with an Olympus FV 1000- 
MPE Microscope set with a Spectra Physics MaiTai Deep See laser, tunable from 710- 
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990 nm, with dispersion compensation for two-photon microscopy (Olympus 
Corporation, Tokyo, Japan). The system is also equipped with two external detectors for 
two-photon imaging, and dichroic mirrors available for collecting blue, green and red 
emissions.  Emitted light is collected using a 3-fixed band pass filter system: 420-460 nm 
(blue channel), 495-540 nm (green channel), and 575-630 nm (red channel). It should be 
noted that as we investigated EGFP-based expression, we merged the pseudo-green and 
pseudo-red colors to further differentiate between GFP-based fluorescence and 
endogenous tissue fluorescence. This was done because renal tubules are known to 
have high levels of green autofluorescence. 
 
2.6 Hydrodynamic Retrograde Renal Vein Delivery to the Kidney of Live Rat 
      We adapted the injection process outlined above to incorporate vascular cross-
clamping as a means to potentially reduce exogenous substance leakage and renal 
uptake. For this technique, we first clamped the renal artery, followed by the renal vein, 
using micro-serrefines. The vein was then elevated with either 3-0 or 4-0 silk loops. At 
that time either a tissue dye or transgene suspension was infused retrograde into the 
vein as previously outlined. The needle was removed. And a cotton swab was applied to 
the injection site to induce hemostasis. The venous clamp was removed first, and then 
arterial clamp was removed. The total clamping period lasted no more than 3 minutes. 
After this, the midline incision was closed and the animal was allowed to fully recover. 
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2.7 Western Blot Analysis 
      Whole kidneys were extracted from anesthetized rats, the cortex from kidneys was 
excised and homogenized in RIPA buffer(150mM NaCl, 50mM Tris -Cl PH 8.0, 1%Triton 
X-100, 0.5% Sodium Deoxycholate, 0.1% SDS). 
      The extracts (3 µg protein/lane) were separated through the10% Bis-Tris Mini Gels 
(Novex® by Life Technologies TM, Cat. # NP0301), along with 7.5ul molecular weight 
markers (Precision Plus Protein TM Dual Color Standards, BIO-RAD, Cat. # 616-0374). 
Proteins were electroblotted to nitrocellulose membrane. The membrane was blocked 
by incubation in TBS with 3% FBS for 12h at 4°C. Membranes were incubated with 
primary antibody in TBS with 0.3% FBS for 1hour at room temperature. After three 
washes, the membrane was incubated with appropriate secondary antibody HRP D&R in 
antibody dilution buffer at room temperature for 1 hour. After three washes, the 
immunoreactive bands were visualized by chemiluminescence using SuperSignal™ West 
Pico Chemiluminescent Substrate (Thermo Scientific, Cat. # 34080). 
 
2.8 In Situ PCR 
      Whole rat kidney sections were washed in cold RNase-free PBS. Tissues were fixed in 
4% paraformaldehyde-sucrose at 4°C for 18 h. Fixed tissues were mounted in optimum 
cutting temperature compound (Polysciences, Warrington, PA), and 5- to 7-mm 
cryosections were mounted and placed onto RNase-free Probe-On Plus slides. The slides 
were kept at -80°C until used for direct in situ PCR. Tissue digestion conditions were 
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standardized by performing digestions in 1 unit/ mL proteinase K for a fixed time. For 
standardization of digestion conditions, the digestion time of the enzyme, which did not 
change the histoarchitecture of the renal tubules, was monitored under a light 
microscope at 2- to 3-min intervals until an optimal digest time was achieved. Enzyme 
digestions were stopped by incubating the slide for 1 min at 65°C in PBS buffer. 
       The slides were then immersed at room temperature in 1 unit/ml proteinase K 
(Invitrogen, P/N 100005393) solution for 1.5 min, 2min, and 3 min, or in ddH2O. After 
proteinase K treatment, the slides were incubated in 65°C PBS for 1min.  
      For amplification of the target IDH2/SULT1C2 sequence, PCR was carried out in situ 
on the sections using an MJR PTC-100 thermal cycler. Slides were kept at 4°C before the 
start of the PCR reaction. 20µl PCR mix was overlaid on the sections, and the slide was 
sealed with adhesive coverslips (Sigma, St. Louis, MO). Reactions were performed in the 
presence of 1X AccuPrime™Pfx Reaction Mix 0.3 mM, 0.3µM 5’ forward and 3’reverse 
primer, and 2.5 units of AcciPrime™Pfx DNA polymerase (Invitrogen, Cat No. 12344-
024). The MgSO4 is included in the 10X AccuPrime™Pfx Reaction Mix (Invitrogen, P/N 
55013) at a final concentration of 1mM. dNTPs are included in the10X AccuPrime™Pfx 
Reaction Mix at a final concentration of 0.3mM. The 3’ primer (5’-TGA CTG GGC ACA 
ACA GAC AAT -3’). The 5’ primer (5’- GAT CGA CAA GAC CGG CTT -3’) was conjugated to 
Cy5. Primers were synthesized by Integrated DNA Technologies. 
      Slides were sealed with a colorless nail polish. PCR was carried out for one cycle at 
95°C for 2 min, followed by 30 cycles with denaturation at 95°C for 15 s, annealing at 
48.2°C for 5 s, and extension at 72°C for 50 s. When the PCR was complete, samples 
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were kept at 4°C. Coverslips were removed, slides were soaked for 1 min in 1X PBS at 
room temperature, counterstained with hematoxylin, and rinsed with 1X PBS and 
double distilled water. Samples were overlaid with Permount (Fisher Scientific) and 
covered with coverslips. 
      Samples were imaged with a Zeiss LSM 510 confocal microscope equipped with 
argon and helium/neon lasers. Samples were excited at 633 nm of light, and images 
were collected with a 650-nm emission filter in the light path. All images were collected 
using standardized laser intensities and photomultiplier tube settings for amplification 
and dark levels. 
 
2.9 Mitochondria Respiration Assay 
 
2.9.1 Homogenization 
      After the kidney was harvested from the rat, the capsule layer was peeled and the 
cortex was shaved off. At 4°C the cortex was gently homogenized with Mitochondrial 
lysis buffer(250mM sucrose, 20mM HEPES, 10mM KCL, 1.5mM, MgCl2,1.0mM EDTA , pH 
7.9) using a Wheaton Teflon pestle and 15mL homogenization tube. 
 
 
 
42 
2.9.2 Mitochondria Purification 
            The homogenate was spun at 750×g for 10min at 4°C. The supernatant was 
transferred to different microfuge tube and spun at 10,000×g for 10min at 4°C. The 
supernatant was removed, the pellet was resuspended in 1ml of Lysis buffer and was 
spun at 10,000×g for 10min at 4°C. After a total of 3 washes, the pellet was resuspended 
in 1ml lysis buffer and kept on ice with caps open.  
             The concentration of mitochondria fraction was determined by Bio-Rad Protein 
Assay Dye Reagent Concentrate (Bio-Tek Instruments, Inc.). 
 
2.9.3 Mitochondria O2 Consumption Measurement 
      Before starting each experiment, the O2 electrode of the Oxygen Meter (Model 
5300, Yellow Springs Instrument Co.) was calibrated. The electrode was surrounded by a 
temperature-controlled water-jacketed glass chamber maintaining the temperature at 
37°C. 
      The mitochondrial fraction was diluted to 1-3μg/μL using the Terzic Buffer (110mM 
KCL, 5mM K2HPO4·3H2O, 10mM MOPS, 10mM Mg·Acetate, 1mM EDTA, 1μM 
tetrasodium pyrophosphate, 0.1% BSA, pH 7.15) for a total volume of 2.5ml and was 
then transferred into O2 chamber with stirring. 
      The electrode was gently inserted into the chamber. The O2 percentage was 
recorded when the following substances were added every 1 minute in the following 
order: Terzic buffer; substrate（1M succinate or 1M pyruvate), and ADP. The 
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substances were injected by Hamilton syringe to give a final concentration of 10mM in 
the chamber. At 10 minutes, the record of mitochondria respiration was stopped. 
 
2.10  DNA Agarose Gel Electrophoresis 
      The E-Gel® with SYBR Safe 1.2% agarose gel (Invitrogen, G521801) was inserted into 
the E-Gel® PowerBase™v.4.  Each well of the gel was loaded with 500ng plasmid DNA. 
The electrophoresis time was set as 30 min. 
 
2.11 Laurdan Mitochondria Fluidity Assay 
      The mitochondria fraction was extracted in the same way as the mitochondria O2 
consumption assay. When the kidney was harvested from the rat, the capsule layer was 
peeled and the cortex was shaved off. At 4°C the cortex was gently homogenized with 
mitochondrial lysis buffer using a Wheaton Teflon pestle and 15mL homogenization 
tube, and the mitochondria fraction was purified by several rounds of centrifugation at 
4°C. 
      The mitochondrial fraction was mixed with Laurdan in the ratio of 300:1, and the 
mixture was loaded into 96 wells plate and incubated at 37°C for 5 minutes with the 
plate covered. The fluorescence emission intensity was acquired at 440nm and 490nm 
(excitation= 355 nm) at 37°C using the spectrofluorimeter. 
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      Generalized polarization (GP) was calculated from the emission intensities using the 
following equation adapted from the work of Parasassi et al. : GP = I440−I490
I440+I490
 .(I440 and 
I490 refer to the average emission intensities at those wavelengths.) 
 
2.12 Statistical Analysis 
      We computed the mean and S.E. for all data sets, and evaluated the statistical 
significance of our results using the Student’s t-test. All statistical analyses were 
evaluated using 95% confidence threshold. 
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CHAPTER 3. RESULTS 
3.1 Hydrodynamic Fluid Delivery Facilitates Reliable Transgene Expression in Sprague 
Dawley Rats 
 
3.1.1 Fluorescent Protein Expression in Cultured Cells Using Plasmid Vector 
      We observed non-viral and viral derived fluorescent protein expression in cultured 
cells using confocal microscopy (Figure 5). Occludin is an integral plasma-membrane 
protein located at the tight junctions. In the cells treated with EGFP-occludin (Figure 5B) 
fluorescent signals were detected on the membrane, which showed anticipated probe 
localization. Fluorescent H2B-tdTomato protein expression was observed throughout 
the nuclei of transfected cells (Figure 5C). 
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3.1.2 Plasmid Expression in Renal Cells with Retrograde Hydrodynamic Renal Vein 
Delivery 
      Dr. Corridon performed hydrodynamic injections augmented with vascular cross-
clamping. These injections generated widespread fluorescent protein expression lasting 
over a month after the introduction of non-viral transgenes. 
      Using plasmids we successfully transfected live rat kidneys with EGFP occludin 
(Figure 6A), and H2B-tdTomato (Figures 6B and 6C). Fluorescent protein was observed 
1) in proximal and distal tubules; 2) within glomeruli; 3) within the peritubular 
interstitium; 4) within the renal capsule; and 5) within the perirenal fat. 
      Images obtained from live rats that expressed EGFP-occludin and H2B-tdTomato 
plasmid-derived fluorescent proteins provided clear signs of the expected probe 
localization and morphology. EGFP-occludin expressed in proximal tubule cells. EGFP-
occludin fluorescence signals ran between adjacent nuclei as punctate fluorescent 
bands along regions that correspond to tight junctions (Figure 6A). The H2B-tdTomato 
signals colocalized with Hoechst counterstained nuclei (Figures 6B and 6C).
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Figure 5. Plasmid-derived fluorescent protein expression in live cells. Confocal laser 
scanning micrographs obtained from S3 proximal tubule epithelial mouse cell cultures 
incubated with: (A) Null vector; (B) EFGP-occludin plasmid vectors; and (C) Histone H2B-
tdTomato plasmid vectors. These images were taken 1 day after plasmid 
transformation. Image (B) outlines characteristic plasma membrane-derived tight 
junction staining and (C) presents typical nuclear and cytoplasmic staining representing 
histone localization. 
 
 
 
 
Figure 6. Hydrodynamic delivery facilitates the expression of a variety of plasmid 
vectors in live rat kidneys. Transgene expression is observed in proximal tubule cells 
(A), distal tubule cells (B), and within the renal capsule (C). These images were taken 
from live rats 3 days after receiving hydrodynamic injection of EGFP-occludin (image A), 
H2B-tdTomato (images B and C). Arrowheads indicate regions of transgene expression. 
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3.1.3 In Situ PCR Confirmed the Hydrodynamic-Based Transgene Amplification 
      The primers used for in situ PCR were designed against the Kanamycin resistance 
gene contained in both SULT1C2 and IDH2 plasmid vectors, and so will uniquely identify 
the exogenous transgenes. The upper primer was labeled with Cy5. The fluorescent 
labels permitted direct visualization of plasmid delivery by confocal microscopy. 
      Before in situ PCR, we optimized the PCR conditions using SULT1C2 plasmid as 
template. The 375bp size PCR product band was shown in DNA agarose gel (Figure 7).  
      One group of Sprague Dawley rats were subjected to hydrodynamic SULT1C2 
plasmid injection, while the control group received saline injection. The kidney tissue 
sections were pre-treated with 1 unit/mL Proteinase K solution. Proteinase K can 
denature the proteins in tissue and inactivate DNases and RNases. Proteinase K is also 
used to increase the permeability of the kidney tissue to enable the effective PCR 
reaction. At first, we digested the kidney sections from the rats subjected to SULT1C2 
delivery with proteinase K for 3 min, and then performed in situ PCR with primers and 
Taq polymerase. In the initial experiments, the tubule structures were destroyed by 
over-digestion with proteinase K and the high temperature cycles of the PCR reaction 
(Figure 8A). Then we tested the digestion time by treating the sections with proteinase K 
for 2min (Figure 8B) and 1.5min (Figure 8C). With no proteinase K digestion, the kidney 
structure was maintained, but the fluorescent signal was weak (Figure 8D). The proximal 
tubule segments of the sections treated with 1.5 min digestion better retained their 
structure than those treated with 2 min digestion (Figure 8B and Figure 8C). Though the 
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tubules structure was still altered with 1.5 min digestion, the fluorescent signals were 
much stronger than those of the sections without proteinase K digestion. Thus, 1.5 min 
proteinase K incubation was selected as the optimal condition for the digestion. 
      With 1.5 min digestion, little fluorescent signals was noted in samples imaged 
without in situ PCR (Figure 9A and 9D). When the in situ PCR reaction was performed on 
kidney sections without Taq polymerase, only weak fluorescent signals were detected 
(Fig 9B and 9E). In contrast, when direct in situ PCR was performed with all necessary 
primers and Taq polymerase in the tissue section that subjected to SULT1C2 plasmid 
injection, significant levels of additional fluorescent signals were observed in proximal 
tubule segments (Fig 9F). There was only weak signal in kidneys from saline-injected, 
control rats. This data demonstrates that plasmid DNA is being delivery to the cytosolic 
compartment of renal tubule epithelial cells. Therefore hydrodynamic delivery of 
plasmid DNA is effective in delivering. 
 
3.1.4 Overexpression of Transgene Expression Confirmed via Western Blot 
      Four groups of rats received, respectively, hydrodynamic delivery of IDH2 plasmid, 
SULT1C2 plasmid, or saline alone, or were subjected to ischemic preconditioning. 
Samples of the kidney cortex were subjected to Western blotting. We observed 
increased levels of IDH2 or SULT1C2 expression in rats that received hydrodynamic 
delivery of the corresponding transgene or ischemic preconditioning, as compared to 
the levels present in the control rats (Figure 10A and 10B). By densitometry of the 
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Western blot, IDH2 expression in the IDH2-delivered rats was 2.2 fold higher than in 
vehicle control rats. The IDH2 expression of preconditioned rats was 2.8 fold higher than 
in control rats (Figure 10C). The expression level of SULT1C2 in rats that received 
hydrodynamic delivery and ischemic pre-conditioned was respectively 5 fold and 3.5 
fold higher than control rats (Figure 10D). 
      The Western analysis outlined above clearly demonstrates the upregulation of the 
mitochondrial enzymes facilitated both by hydrodynamic IDH2 and SULT1C2 gene 
delivery and by ischemic preconditioning. 
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Figure 7. 1.2% Agarose gel electrophoresis of PCR amplified Kanamycin resistance 
gene from the plasmid vectors. Lane M, 1kb DNA Ladder Marker. Lane 1 and 2 showed 
PCR primers amplified the Kanamycin resistance gene sequence (375bp) of the plasmid. 
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Figure 8. Optimization of direct in situ PCR in kidney tissue conditions using different 
digestion times. Before the in situ PCR reaction, hydrodynamic SULT1C2 delivered 
kidney tissue sections were digested by proteinase K for (A) 3min, (B) 2min, and (C) Null 
digestion.  
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Figure 9. Direct in situ PCR in kidney tissue sections (1.5 min digestion). In saline 
injected kidney tissue sections, (A) Background fluorescence, no in situ PCR; (B) In situ 
PCR performed without Taq polymerase; (C) In situ PCR performed with all necessary 
primers and Taq polymerase. In hydrodynamic SULT1C2 delivered kidney tissue sections, 
(D) background fluorescence, no in situ PCR; (E) In situ PCR performed without Taq 
polymerase; (F) In situ PCR performed with all necessary primers and Taq polymerase. 
Bar = 10 µm 
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Figure 10. Western blot analysis of levels of IDH2 protein and SULT1C12 protein 
expression in rat kidneys. Western blot analysis was conducted on tissue sections 
obtained from rats after various treatment as indicated in the captions in (A) and (B): 
hydrodynamic injection of IDH2, SULT1C2 and saline, or rats that were subjected to 
ischemic preconditioning. Analyses of band intensity on films are presented as the 
relative ratio of IDH2 (C) and SULT1C2 (D) to actin. *P> 0.05 versus Preconditioned. 
#P<0.05 versus Vehicle. 
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3.2 Hydrodynamically Delivered Mitochondrial Protein IDH2 Protects Sprague Dawley 
Rat Kidneys against Mitochondrial Dysfunction Following Moderate 
Ischemia/Reperfusion Injury 
      Two vehicle groups of rats received hydrodynamic delivery of saline alone, while one 
group of rats received IDH2 plasmid delivery. 7 days later, one of the vehicle groups and 
the IDH2 delivered group were subjected to 40min unilateral ischemia (moderate injury 
in rats) and 1 h reperfusion. Mitochondrial fractions were isolated from the cortexes of 
the kidneys of the rats and applied to the mitochondrial activity assay. 
      After ischemic reperfusion injury, the mitochondrial oxygen consumption rate in 
State III was measured. The results of mitochondria respiration assay by O2 consumption 
are shown (Figure 11). Using succinate as substrate, after 1h ischemic reperfusion injury, 
the mitochondria respiration remained significantly depressed compared to sham injury 
controls. Following IDH2 delivery and IRI, the mitochondria respiration was significantly 
higher than that of the IRI rats that received vehicle (saline) alone. Moreover, the 
mitochondrial respiratory rate was not markedly decreased as compared to sham 
controls (Figure 11A). We repeated the mitochondrial respiration assay using pyruvate 
as substrate. Overall, the same results were observed: overexpression of IDH2 protected 
the normal level of mitochondrial respiration when the kidney was subjected to IRI 
(Figure 11B). 
      These data demonstrate that upregulation of IDH2 facilitated by hydrodynamic IDH2 
gene delivery results in a protection of mitochondrial respiratory function following IRI. 
Mitochondria are unique in that not only are they the site of energy production but also 
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a central locus in the regulation of cell death [141, 142]. Mitochondria respiration was 
markedly impaired after ischemic injury, while the overexpression of IDH2 facilitated by 
hydrodynamic delivery ameliorated the depression of respiration. This provides a 
plausible explanation for the reduced renal injury observed in previous studies using 
serum creatinine. 
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Figure 11. Overexpression of IDH2 increases mitochondrial respiratory rate. The 
mitochondrial fraction was extracted from the kidneys of the rats received 
hydrodynamic saline (control) injection IDH2 injection, or ischemic preconditioning. (A) 
Mitochondrial respiration with succinate with ADP (state III) is elevated (B) 
Mitochondrial respiration with succinate with ADP (state III) is elevated. The values are 
mean ± S.D. of nine male rats each.*P <0.05 versus vehicle w injury, #P > 0.05 versus 
vehicle. 
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3.3 Ischemic Preconditioning Alters the Mitochondrial Membrane Fluidity of Sprague 
Dawley Rat Kidneys Following Moderate IRI 
      Laurdan is a fluorescent probe that alters its fluorescent properties in response to 
membrane fluidity [143]. In this study, it was utilized to detect changes in mitochondrial 
membrane fluidity.  
      Mitochondrial damage is a major contributor to renal tubular cell death during acute 
kidney injury. During tubular cell injury, mitochondrial damage could involve 
impairment of respiration complexes, loss of mitochondrial membrane potential, and 
increasing permeability of the mitochondrial membrane. It is plausible that membrane 
fluidity changes could be closely linked to mitochondria dynamics. In theory, when the 
kidneys are subjected to ischemic reperfusion injury, the membrane of mitochondria 
could become more or less ordered (altered fraction of liquid-crystalline vs. gel-like 
state). We predicted that SULT1C2 could protect the kidney against ischemic injury by 
ordering the mitochondria membrane. To begin these studies, we first investigated the 
effect of ischemic preconditioning on mitochondria membrane fluidity. 
      The mitochondria fraction was isolated from the kidney cortexes of various groups of 
rats. From the data of Laurdan assay, the GP values of the sham rats with 1h IRI were 
markedly increased compared to the normal value (Figure 12). This indicates that the 1h 
ischemic reperfusion injury decreased mitochondrial membrane fluidity.  
      Though the GP value of the ischemic preconditioned rats was slightly higher than 
that of the normal rats, there was no significant difference of the fluidity between the 
two groups (Figure 12).  The GP value of the preconditioned rats subjected to IRI was 
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remarkably higher than that of ischemic preconditioned rats. We can conclude that 
ischemic preconditioning affects makes the membrane more susceptible to alterations 
caused subsequent IRI leading to overall ordering of the mitochondria membrane.  
      Compared with the two groups subjected to IRI only, the GP value of the 
preconditioned rats was dramatically increased. Despite the evidence that ischemic 
preconditioning ordered the mitochondria membrane of the rats subjected to 
subsequent IRI, we cannot draw a hasty conclusion that reduced mitochondrial 
membrane fluidity play a role in protecting kidney from IRI. This is because the ischemic 
injury also led to a decrease in membrane fluidity. The 1h ischemic reperfusion injury 
could trigger the dysfunction of mitochondria by decreasing mitochondria membrane 
fluidity. Our expectation was that Ischemic preconditioning would counteract the effect 
of subsequent injury on membrane fluidity.  This was clearly not supported by our 
laurdan assay. When the preconditioned kidney is subjected to IRI, the kidney is injured 
twice. The dramatically reduced mitochondrial membrane fluidity of the injured 
preconditioned kidney showed that the more injury events the kidney was subjected to, 
the more ordered the mitochondrial membrane was.   
      In conclusion, both ischemic preconditioning and ischemic injury reduced the fluidity 
of mitochondrial membrane against renal ischemic injury.  In addition mitochondrial 
membrane fluidity decreased with increasing times of renal ischemic injury.  
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Figure 12. Mitochondrial membrane fluidity changes resulting from varied treatment 
to kidneys. Mitochondrial membrane fluidity was quantified from the GP value of 
Laurdan in mitochondrial extracts. The values are mean ± S. D. of four male rats each. 
*P< 0.05 versus sham, #P< 0.05 versus preconditioning w injury. 
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3.4 Effects of Ischemic Preconditioning on the Mitochondria Isolation 
      From our laurdan data, we cannot draw a conclusion that IP can protect kidney 
against IRI via regulating mitochondria membrane fluidity. Ischemic preconditioning 
should take effect on the kidney by other pathways. There is evidence that 
mitochondrial structures is altered in kidney cells following ischemic injury. This has the 
potential to affect the yield of mitochondria in our preparations. We measured the yield 
of mitochondria in the fractions used for the laurdan assay, and attempted to 
investigate whether ischemic preconditioning can increase the yield of mitochondria in 
kidney, for example by causing fragmentation or aggregation of mitochondria. 
      As mentioned earlier, the mitochondrial fraction was extracted from kidney cortices. 
The fraction was resuspended in 1mL lysis buffer. Bradford protein assay was applied to 
measure the concentration of the mitochondrial fraction. The total yield of 
mitochondria for each group were calculated (Figure 13). 
      The yield of mitochondria in the fraction extracted from the preconditioned kidneys 
with subsequent IRI was significantly higher than that either from the sham kidneys or 
that from the preconditioned kidneys without subsequent IRI. The yield of mitochondria 
extracted from the ischemic injured kidneys was larger than that of sham kidneys and 
the preconditioned kidneys without subsequent IRI, but less than that of the 
preconditioned kidneys with subsequent IRI. There was no significant difference 
between the yield from ischemic injured kidneys and preconditioned kidneys with 
subsequent injury (Figure 13). 
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      Our data demonstrates that when kidneys were preconditioned and subjected to 
subsequent IRI, there was an increase in isolated mitochondria yield from these kidneys. 
But the kidneys subjected to IRI also had relatively higher yield of mitochondria. It is not 
clear that the changes in mitochondrial yield reflect systematic differences between 
treatments. The amount of mitochondria we measured could be influenced by many 
other factors. The size of each kidney was different and the total weight of the cortices 
shaved from the kidney was also different. These confounding variables make it 
impossible to draw conclusions about the differences in isolated mitochondria fractions. 
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Figure 13. Yield of extracted mitochondrial fraction varied by different treatment. The 
values are mean ± S. D. of four male rats each. *P< 0.05 versus Preconditioned w/ injury. 
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CHAPTER 4. DISCUSSION 
4.1 Summary 
      Firstly, with the help of Dr. Corridon, we tested the efficiency of hydrodynamic 
plasmid delivery technique by delivering fluorescent plasmid vectors to the kidney.  The 
EGFP-occludin and H2BtdTomato plasmids were expressed in the proper location and 
morphology. This shows the usefulness of this technique for expression fluorescent 
probes and biomarkers in the kidney. 
      Secondly, I presented results obtained from the in situ PCR and Western blot analysis 
that were conducted to prove that hydrodynamic fluid method facilitated non-viral 
transgene delivery in the rat kidney. In these studies, we delivered plasmid vectors 
encoding two genes, IDH2 and SULT1C2 to Sprague Dawley rat kidneys, using 
hydrodynamic retrograde venous injections.  
      These genes were previously identified to be upregulated in Sprague Dawley rats 
subjected to ischemic preconditioning. Immune blot analysis confirmed the 
upregulation of protein expression of these mitochondria-associated proteins in rats 
that received hydrodynamic injections of the IDH2 and SULT1C2 plasmids. Western blot 
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analysis also provided the first independent confirmation of the proteomic results, 
showing that ischemic preconditioning does significantly  increase the levels of IDH2 and 
SULT1C2. 
      Thirdly, we identified that hydrodynamic injection of IDH2 plasmid protected rat 
kidneys against moderate IRI. This protective effect was seen both with serum assays of 
kidney function (serum creatinine) and using in vitro assays of mitochondrial respiration. 
As an essential enzyme in TCA cycle, IDH2 is supposed to affect mitochondria activity 
through mitochondrial respiration. Sprague Dawley rats that received hydrodynamic 
venous injections of IDH2 plasmid were exposed to moderate IRI. Strikingly these rats 
appeared to be resistant to this injury, as their mitochondrial respiration was normal.    
      Fourthly, we focused on the mitochondrial membrane fluidity study. We also 
expected that preconditioning could counteract the effect of IRI on membrane fluidity. 
Our results actually ran counter to the latter hypothesis. GP values showed that 
ischemic preconditioning actually potentiated the changes in membrane fluidity 
resulting from IRI. Thus, it seems unlikely that preconditioning or levels of IDH2 and 
SULT1C2 protect mitochondria against IRI by regulating mitochondrial membrane 
fluidity. 
      Finally, we measured the total amount of the mitochondrial fraction extracted for 
the fluidity study to investigate the effect of ischemic preconditioning on the quantity of 
renal mitochondria. Since many variables can affect mitochondria levels in the kidney, 
future studies are needed to determine if ischemic preconditioning can increase the 
amount of mitochondria present in the kidney.
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4.2 The Effect of Hydrodynamic Fluid Delivery on Transgene Uptake in Normal Rats 
      Hydrodynamic retrograde fine-needle renal vein injection has been shown to be 
efficient and to generate minimal injury and disruption to regular renal function in 
previous studies in our lab. We first verified the quality of our plasmid transgene vectors 
in cell culture before conducting in vivo studies. EGFP-occludin fluorescence signals ran 
between adjacent nuclei as punctate fluorescent bands along regions that correspond to 
tight junctions. Fluorescent H2B-tdTomato signals colocalized with Hoechst 
counterstained nuclei. 
      After completing these in vitro studies, we began our transgene delivery studies in 
live animals. Transgene expression was examined in live animal kidneys with intravital 
two-photon fluorescence microscopy. Using hydrodynamic retrograde venous injections 
to deliver plasmid vectors, we detected fluorescent protein expression in the kidneys. 
      We hypothesized that forces produced by this hydrodynamic delivery method may 
facilitate endocytic uptake and expression of exogenous transgenes encoding IDH2 and 
SULT1C2 throughout the kidneys, although at present we do not have evidence that 
supports any particular mechanism by which this procedure facilitates expression. 
      Once we established that this delivery method could reliably facilitate efficient 
fluorescent protein expression in the rat kidney, we considered whether this method 
could be used as a way to help physicians in the management of AKI. In doing so we 
investigated the possibility of delivering genes encoding SULT1C1 or IDH2. The 
hydrodynamic delivery of plasmid vectors that encoded these proteins provided 
resistance against AKI in rats (in rats with two kidneys and uninephrectomized rats) that 
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were subjected to moderate IRI, based on serum creatinine measurements by Dr. 
Corridon. This demonstrates the ability of this method to achieve sufficient expression 
of transgenes to affect the pathophysiology of injury. 
      Transferred exogenous genes was detected in the rats subjected to hydrodynamic 
transgene injection via in situ PCR.  The primers were designed against the gene of 
Kanamycin resistance carried by the plasmid vector of IDH2 and SULT1C2 (Figure 13). 
The kanamycin resistance gene is used as a selective marker for exogenous plasmids not 
naturally occurring in mammalian cells and organisms such as bacteria or yeast. This 
design solved the problem of nonspecific amplification or of amplification of the 
endogenous IDH2 or SULT1C2. The upper primer was labeled with fluorescent dye Cy 5, 
which was used as probe for detection and localization of target transgene in tissue 
sections. When the in situ PCR reaction was performed without Taq polymerase, weak 
fluorescence signals were imaged in the tissue sections. In contrast, when direct in situ 
PCR was performed on the sections with all necessary primers and Taq polymerase, 
significantly stronger fluorescent signals were observed in proximal tubule segments of 
the rats that received hydrodynamic SULT1C2 plasmid delivery compared to that of 
control rats with saline injection. Since the primers were designed for the kanamycin 
resistance gene which was also contained in IDH2 plasmid, we can predict that stronger 
fluorescent signals should be observed in IDH2 delivered tissue sections. This result 
indicates that hydrodynamic injection is sufficient to deliver transgenes to the kidney 
proximal tubules and facilitate the endocytosis of exogenous plasmids. 
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      This result is also in agreement with the Western blot data, which shows the 
expression levels of IDH2 or SULT1C2 of the plasmid delivered rats are significantly 
higher than that of the control rats. In addition, IDH2 and SULT1C2 is overexpressed in 
the rats that subjected to ischemic preconditioning. The upregulated expression of 
IDH2 or SULT1C2 confirmed to us that hydrodynamic fluid delivery facilitates the 
expression of transgenes and was also used to confirm the results of the proteomic 
studies, showing increase expression of these proteins following ischemic 
preconditioning. 
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              Figure 14. pCMV6-Entry Plasmid vector maps of IDH2 (A) and SULT1C2 (B). 
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4.3 Hydrodynamic-based Transgene Expression Enhances Mitochondrial Activity in 
Rats with Moderate IRI 
      The hydrodynamic delivery of plasmid vectors that encoded IDH2 and SULT1C2 
provided resistance against AKI in rats that were subjected from moderate IRI, based on 
serum creatinine measurements. These genes have been suggested to enhance the 
activation of specific pathways in mitochondria that provide protection from IRI.  
      This phenomenon was first suggested from ischemic preconditioning studies 
conducted in rats. Ischemic preconditioning is an experimental technique that has been 
applied to produce resistance to induce resistance reductions in blood and oxygen 
supplies. From a mechanistic perspective, ischemic preconditioning has been studied for 
the past 50 years, during which time many ideas have been put forward to outline its 
organ protective role [144].  
      For instance, in the context of myocardial ischemia, there has been much debate 
about whether the mechanism involves vascular recruitment as a means of improving 
myocardial oxygenation by bypassing the site of occlusion [145].  Other studies have 
implicated mitochondria as key mediators of ischemic preconditioning. Specifically, it is 
proposed that the opening the mitochondrial ATP-sensitive potassium channel or 
mitoKATP plays an important role in producing the protective effect of ischemic 
precondition. Ischemic preconditioning has been shown to reduce post-ischemic tissue 
hyper-oxygenation as it preserves NADH dehydrogenase and cytochrome c oxidase, thus 
maintaining more normal consumption of oxygen. 
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     These events work to prevent oxidative stress, and increase tissue viability on 
reperfusion [146].Mitochondrial enzymes IDH2 and SULT1C2 have been shown to be 
upregulated in Sprague Dawley rats kidneys subjected to ischemic preconditioning, and 
aids in the animal’s ability to resist IRI. 
      Once we confirmed that the delivery method could reliably facilitate efficient IDH2 
and SULT1C2 expression in the rat kidney, we considered whether IDH2 or SULT1C2 
transgene treatments were sufficient to blunt the effect of IRI in Sprague Dawley rats. 
We delivered relatively large doses of plasmid vectors that expressed these genes to 
normal Sprague Dawley rat kidneys. The Sprague Dawley is not genetically resistant to 
IRI as compared to, for example, the Brown-Norway rat [147]. Ischemic preconditioning 
is generally done 3-7 days prior to IRI. We waited seven days after the gene delivery 
process and then induced AKI by subjecting these rats to 40 minute unilateral renal 
pedicle cross-clamps. 
      In the previous study of our lab, hydrodynamic retrograde venous injections of either 
plasmid blunts the serum creatinine increases and keeps mitochondrial membrane 
potential in rats with moderate IRI. Upregulation of either mitochondria modifier 
enzyme appeared to have protected renal function from the IRI. So we expected to 
explore how these enzymes protect the kidney from AKI. 
      IDH2 could clearly change mitochondrial function based on its role in the TCA cycle. 
In cellular respiration, metabolites, such as glucose, fatty acids and ketone bodies, are 
oxidized via the TCA cycle to produce reduced NADH and FADH2. Electrons are 
transferred by NADH and FADH2 to ETC complexes embedded in mitochondrial inner 
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membrane. The supply of substrates and oxygen are essential for mitochondria 
respiration. Export of NADH and FADH2 derived from the tricarboxylic acid (TCA) cycle 
plays an important metabolic role in mitochondrial respiration. The oxidation of 
isocitrate by IDH2 is one step in the TCA cycle. This reaction generates not only NADH 
for the electron transport chain, but also α-ketoglutarate delivered to the following 
reactions of TCA cycle. 
      From our mitochondrial respiration data, we determined that IDH2 transgene 
treatment was sufficient to blunt the effect of IRI on mitochondrial respiration in these 
Sprague Dawley rats. Mitochondrial respiration rates in rats that received hydrodynamic 
retrograde venous injections of IDH2 plasmid remained within normal levels despite 
being subjected to moderate IRI, when compared to rats that received saline injections. 
Overexpression of the mitochondrial enzyme IDH2 appeared to have protected renal 
function from IRI by enhancing mitochondrial respiration. Our prediction is that 
increased IDH2 can trigger certain pathways involved in mitochondria respiration, such 
as TCA cycle, electron transport system, and oxidative phosphorylation, to enhance the 
respiration rate against AKI, although considerable work is needed to understand the 
exact mechanisms involved. 
      The potential role that SULT1C2 plays is not obvious from its known function. 
SULT1C2, belongs to sulfotransferase family, is a cytosolic enzyme catalyzing the 
transfer a sulfo-moiety from PAPS to phenol-containing compounds. Since SULT1C2 was 
upregulated in mitochondria resulting from the renal ischemic preconditioning, we 
speculated that the sulfation of the mitochondrial membrane catalyzed by SULT1C2 
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could regulate the fluidity of mitochondria membrane. The fluidity changes of 
mitochondria can be detected by shifts in laurdan emission maximums spectrum from 
440nm to 490nm. The shift of the emission maximum of Laurdan can be quantified by 
the Generalized Polarization (GP) function defined as:  𝐺𝐺𝐺𝐺 = I440−I490
I440+I490
 . The more 
positive the GP value is, the less fluid the mitochondrial membrane is. 
      Ischemic reperfusion injury can trigger an increase in mitochondrial membrane 
permeability. The mitochondrial permeability transition is a key contributor in cell 
apoptosis or necrosis. Therefore we speculated that ischemic reperfusion injury could 
increase the fluidity of mitochondrial membrane and ischemic preconditioning could 
maintain mitochondrial membrane order, which inhibits the mitochondrial permeability 
induced by AKI.   
      The GP value of all the groups of rats were negative, which meant that the 
mitochondria membrane was in the fluid state. Ischemic reperfusion injury led to the 
increasing of the GP value, compared to the normal level. It implied that the ischemic 
injury decreased the mitochondria membrane fluidity. Surprisingly, the mitochondrial 
membrane of the preconditioned rats with subsequent ischemic reperfusion injury was 
significantly more ordered than the ischemic reperfusion injured rats.  
      If ischemic preconditioning plays a role in protecting kidney by regulating 
mitochondria membrane fluidity, we expected it to increase the membrane fluidity, 
acting in the opposite direction to ischemic injury. However, from our laurdan data, like 
ischemic injury, ischemic preconditioning ordered the mitochondrial membrane, which 
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indicates that ischemic preconditioning may not protect mitochondrial function by 
regulating mitochondrial membrane fluidity. Our existing Laurdan data therefore show 
that multiple successive ischemic events decreased the fluidity of mitochondrial 
membrane.  
      There are problems with our laurdan assay that may make this method unsuitable to 
gauge the effect that ischemic preconditioning has on mitochondrial membrane fluidity. 
The fluidity of mitochondria membrane assayed by Laurdan presented the fluidity of the 
total mitochondrial membranes, since laurdan likely partitions into both the outer 
membrane and inner membrane. But the fluidity of the inner membrane of 
mitochondria is most likely the more important parameter to assay.  
      The inner mitochondrial membrane (IMM) is the active site for the electron 
transport chain and ATP production. Its fluidity is largely determined by the composition 
of phospholipids is crucial for mitochondrial function. For example, the activity and 
stability of the oxidative phosphorylation proteins, a significant portion of the IMM 
proteins, are affected by their interaction with phospholipids in the IMM. It has been 
found that complexes III and IV of the oxidative phosphorylation system were 
destabilized in a disordered IMM.  
      Among the IMM proteins, a significant portion of proteins comprises the oxidative 
phosphorylation system, which contains five multi-protein complexes, illustrating the 
importance of fluidity of inner mitochondria membrane for mitochondrial respiration. In 
addition, an ordered inner mitochondria membrane is also involved in the import and 
assembly of proteins. The majority of mitochondrial proteins are encoded in the nucleus 
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and require protein translocases in the mitochondrial membranes in order to be 
imported [148]. The changes of mitochondrial membrane fluidity of both outer 
membrane and inner membrane complicated our analysis and did not allow us to isolate 
effects on the inner membrane alone.  
      As ischemic preconditioning protects kidney from AKI, we investigated other 
potentially protective pathway – whether ischemic preconditioning can increase the 
amount of mitochondria or their organization in a way that affected the yield of 
mitochondria in our assays. We measured the total yields of the mitochondrial fractions 
extracted for the laurdan assay. The data showed that preconditioned kidneys with 
subsequent IRI had dramatically increased mitochondria yield, while the kidneys 
subjected to IRI also had increased yields of mitochondria. The changes in yields of the 
mitochondrial fraction cannot be solely accounted for by ischemic preconditioning 
treatment. Different kidney size and various weights of the cortices shaved from 
different kidneys were the variables that contributed to the results. In addition, if 
ischemic preconditioning treatment could increase the amount of mitochondria in 
kidney, there should be similar amount of mitochondria in the preconditioned kidneys 
with subsequent IRI and the preconditioned kidneys without subsequent IRI. From our 
data, the kidneys treated with ischemic preconditioning alone unexpectedly had lower 
yields of mitochondria.   
      At present, little is known about mitochondrial adaptations in experimental or 
genetic models of resistance. This is an important gap in our knowledge since a variety 
of organisms and tissues have demonstrated adaptations to ischemia/hypoxia or 
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anaerobic conditions by altering mitochondria protein expression. There are knowledge 
gaps in how mitochondria adaptations influence hemodynamics. However, proximal 
tubules are highly dependent on mitochondrial oxidative phosphorylation. Hypoxia or 
I/R injury leads to impaired mitochondrial energetic capacity and/or activation of cell 
death pathways. Post-hypoxic mitochondria are a source of reactive oxygen species, 
which represent a contributing factor toward cellular injury, and may cause 
vasoconstriction. For example, superoxide enhances the effects of other vasoactive 
factors and may have direct actions in reducing renal blood flow [149]. As a result, we 
hypothesized that adaptations in mitochondrial composition confer protection against 
ischemia by altering baseline mitochondria function. These adaptations preserve 
mitochondria integrity in response to injury, leading to cytoprotection and preservation 
of renal hemodynamics. 
      In conclusion, we investigated that hydrodynamic fluid delivery of IDH2 plasmid 
protects kidneys from AKI via enhancing mitochondria respiration. Further studies need 
to be carried out to explore the role SULT1C2 and ischemic preconditioning play in 
protecting kidney from AKI. The potential therapeutic benefit observed in these results 
also provides an exciting platform to facilitate the future management of IRI. Though 
there is long way to go to being able to apply the hydrodynamic-based gene delivery for 
gene therapy, this technique facilitates the study of the protective mechanism pathways 
of ischemic preconditioning. 
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CHAPTER 5. CONCLUSIONS 
      We first showed that hydrodynamic fluid delivery could facilitate the delivery of 
plasmid vectors into live rodent kidneys. Fluorescent plasmids EGFP-occludin and H2B-
tdTomato delivered by hydrodynamic fluid renal injection widely expressed in proper 
localization. The widespread expression of fluorescent plasmid vectors confirmed the 
efficiency of the hydrodynamic fluid delivery technique.  Then IDH2 and SULT1C2 
plasmids were delivered to the kidneys of live Sprague Dawley rats. Via in situ PCR, we 
observed amplified expression of the plasmids in the tissue sections of kidneys 
administered through hydrodynamic transgene delivery. From the immune blot, the 
overexpression of IDH2 and SULT1C2 facilitated by the hydrodynamic gene delivery was 
also observed. 
      Second, we found that hydrodynamic gene delivery could be used to protect rat 
kidneys against moderate IRI by facilitating the upregulation of IDH2 in Sprague Dawley 
rats. Mitochondrial respiration was maintained in the rats that received hydrodynamic 
delivery of IDH2 plasmid and subsequent IRI. The overexpression of IDH2 protects the 
ischemic injured rats through the mitochondria respiration pathway.
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      Third, in order to explore what role SULTL1C2 plays in mitochondria, we utilized 
Laurdan assay to detect if overexpression of SULT1C2 can alter the mitochondria 
membrane fluidity.  To begin with, we completed the study on whether ischemic 
preconditioning can alter mitochondria membrane fluidity to resist subsequent ischemic 
injury. The result is not convincing, because when subjected to renal ischemic injury, the 
fluidity of mitochondrial membrane both ischemic preconditioning treated rats and 
sham rats was decreased. It cannot be concluded that ischemic preconditioning can 
protect kidneys against AKI by regulating mitochondria membrane fluidity. In the future 
study of membrane fluidity, other experimental methods need to be employed to 
investigate the changes of mitochondria membrane fluidity.   
      In conclusion, our studies demonstrated that hydrodynamic fluid delivery of IDH2 
plasmid can lessen cell damage caused AKI due to improved mitochondria respiration. 
Further studies are needed to explore p methods to measure mitochondria membrane 
fluidity and investigate how ischemic preconditioning and overexpression of SULT1C2 
can alter the fluidity of membrane to protect the kidney from AKI. 
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CHAPTER 6. FURTHER STUDIES 
      How the ischemic preconditioning and hydrodynamic-based SULT1C2 plasmid 
delivery prevents kidneys from AKI will be the major tasks for the following study. We 
will continue to utilize the mitochondrial oxygen consumption study of the Sprague 
Dawley rats administered through ischemic preconditioning or hydrodynamic fluid 
delivery of SULT1C2 plasmid to examine whether overexpressed SULT1C2 or ischemic 
preconditioning can enhance mitochondrial respiration to protect kidney against AKI. 
      For the mitochondrial membrane fluidity study, polarized-fluorescence spectroscopy 
is a rapid and traditional method to detect overall changes in membrane fluidity. 
Besides Laurdan (6-Dodecanoyl-2-Dimethylaminonaphthalene), many other fluorescent 
dyes can be used to detect the membrane fluidity. DPH (1, 6-diphenyl-hexa-1, 3, 5-
triene), which is one of the classical probes used for fluorescence polarization 
measurements [150].  
      The spin-labeling technique with electron spin resonance can be introduced to 
determine membrane fluidity in plasma membranes, too [151]. But the fluidity 
measurement of inner mitochondria membrane is more complicated. One method is to 
use a polarity-sensitive fluoroprobe to selectively bind to inner mitochondrial 
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membrane. Cardiolipin, known as the signature phospholipid of the inner mitochondrial 
membrane, can be used as a potential target of inner mitochondrial membrane [152]. 
      Though our data indicate that hydrodynamic-based IDH2 plasmid delivery increases 
mitochondria respiration, the role IDH2 plays in the respiration pathway still needs in-
depth analysis. For example, by testing whether the catalytic activity of the enzyme is 
actually required. 
      Our study demonstrates our hypothesis that hydrodynamic retrograde venous 
injections can be used to effectively deliver mitochondrial specific genes that can 
protect mammalian kidneys from acute kidney injury generated from 
ischemia/reperfusion injury. In the future, this technique can by employed to facilitate 
the delivery of other genes that have been reported to be upregulated in kidneys of rats 
that are resistant to moderate ischemia-reperfusion injury.  This gene delivery method 
can enable scientist to investigate the pathways of the genes take effect in kidneys. 
Hydrodynamic gene delivery has the potential to aid researchers in their pre-clinical and 
translational gene therapy studies in other fields. 
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